The Solubility - Intrinsic Dissolution Rate of Diazepam and Inclusion Complexes Diazepam with 2-Hydroxypropyl-β-Cyclodextrin
International Journal of Science, Technology and Society
Volume 1, Issue 1, July 2013, Pages: 24-35
Received: May 15, 2013;
Published: Jun. 10, 2013
Views 3542 Downloads 484
Hadžiabdić J., Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Sarajevo, Sarajevo, Bosnia and Herzegovina
Elezović A., Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Sarajevo, Sarajevo, Bosnia and Herzegovina
Hadžović S., Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Sarajevo, Sarajevo, Bosnia and Herzegovina
Vehabović M., Bosnalijek d.d., Sarajevo, Bosnia and Herzegovina
When the fast absorption of diazepam is needed in order to suppress febrile convulsions and epileptic seizures, the most suitable is intravenous application diazepam. To avoid inappropriate self administration of such diazepam dosage form, orodispersible tablets of diazepam would be the dosage form of choice. Poor solubility of diazepam in water is directly related to its dissolution rate after release from a solid dosage form. Inadequate dissolution rate of diazepam can be the limiting factor for its absorption rate. Inclusion complexation of diazepam with 2-hydroxypropyl-β-cyclodextrin was carried out to increase the solubility of diazepam at pH 6.8. Determination of the intrinsic dissolution rate of diazepam as well as complexated diazepam was carried out to predict the absorption rate of diazepam at given pH value. The solubility of micronized diazepam (particle size 5.4 µm) at pH 6.8, was 0.043 mg mL-1, while the solubility of non-micronized diazepam (particle size 414.8 µm) at the same pH was 0.036 mg mL-1. Inclusion complexation of diazepam with 2-hydroxypropyl-β-cyclodextrin resulted in increased solubility of diazepam. One mole of 2-hydroxypropyl-β-cyclodextrin increased the solubility of micronized diazepam 6.82 fold, while two moles of 2-hydroxypropyl-β-cyclodextrin increased the solubility of diazepam 12.55 fold. Given that the values of intrinsic dissolution rates (IDR) of micronized diazepam, non-micronized diazepam and inclusion complex D: 2-HP-β-CD 1:1 were less than 0.1 mg min-1 cm-2, the absorption of diazepam dissolution would be the rate limiting step to absorption, while the inclusion complex D: 2-HP-β-CD 1:2 where an IDR value was greater than 0.1 mg min-1 cm-2 at pH 6.8, suggested that its dissolution might be the rate-limiting step to absorption. Hydroxypropyl-β-cyclodextrin increased the solubility of diazepam at pH 6.8, thus increasing the dissolution rate and causing faster absorption of diazepam at pH 6.8.
The Solubility - Intrinsic Dissolution Rate of Diazepam and Inclusion Complexes Diazepam with 2-Hydroxypropyl-β-Cyclodextrin, International Journal of Science, Technology and Society.
Vol. 1, No. 1,
2013, pp. 24-35.
R. Mandrioli, L. Mercolini, M. A. Raggi, Benzodiazepine metabolism: an analitycal perspective, Curr Drug Metab, 2008, 9, 827-844.
J. Riss, J. Cloyd, J. Gates, S. Collins, Benzodiazepines in epi lepsy: pharmacology and pharmacokinetics, Acta Neurol Scand, 2008, 118, 69-86.
K. Mehta, K. Garala, B. Basu, R. Bhalodia, B. Joshi, R. N. Charyulu, An emerging trend in oral drug delivery technology: rapid disintegrating tablets, J Pharm Sci Technol, 2010, 2, 318-329.
T. G. Kumar, B. Sa, Preparation and evaluation of rapidly disintegrating fast release tablet of diazepam-hydroxypropyl-β-cyclodextrin inclusion complex, Pharmacology and Pharmacy, 2010, 1, 18-26.
T. Loftsson, M. E. Brewster, M. Másson, Role of cyclodextrins in improving oral drug delivery, Am J Drug Deliv, 2004, 2, 261-275.
G. Mosher and D. O. Thompson, "Complexation: Cyclodextrins," in Encyclopedia of pharmaceutical technolo gy, 3rd ed., J. Swarbrick, Ed. New York: Informa Healthcare, 2007, pp. 671-696
M. E. Brewster, T. Loftsson, Cyclodextrins as pharmaceutical solubilizers, Adv Drug Deliv Rev, 2007, 59, 645-666.
Guidance for industry: waiver of in vivo bioavailability and bioequivalence studuies for immediate-release solid oral dosage forms based on a biopharmaceutical classification system, U.S. department of health and human services, food and drug administration (FDA), center for drug evaluation and reasearch (CDER), 2000, pp.1-13.
M. P. Wagh, J. S. Patel, Biopharmaceutical classification sys tem: scientific basis for biowaiver extensions, Inter J Pharm Pharm Sci, 2010, 2, 12-19.
M. G. Issa, H. G. Ferraz, Intrinsic dissolution as a tool for evaluating drug solubility in accordance with the biopharmaceutics classification system, Dissolution Tech nologies, 2011, 18, 6-13.
A. Dahan, J. M. Miller, G. L. Amidon, Prediction of solubility and permeability class membership: provi sional BCS classification of the world’s top oral drugs, AAPS, 2009, 11, 740-746.
V. M. Varma, S. Khandavilli, Y. Ashokraj, A. Jain, A. Dhanikula, A. Sood, S. N. Thomas, O. Pillai, P. Sharma, R. Gandhi, S. Agrawal, V. Nair, R. Panchagnula, Bio pharmaceutical classification system: a scientific frame work for pharmacokinetic optimization in drug research, Curr Drug Metab, 2004, 5, 375-388.
A. M. Dyas and U. U. Shah, "Dissolution and dissolution testing," in Encyclopedia of pharmaceutical technology, 3rd ed., J. Swarbrick, Ed. New York: Informa Healthcare, 2007, pp. 908-928.
L. X. Yu, A. S. Carlin, G. L. Amidon, A. S. Hussain, Feasi bility studies of utilizing disk intrinsic dissolution rate to classify drugs, Int J Pharm, 2004, 270, 221–227.
B. Y. Wang and O. R. Williams III, „Powders," in Remington The science and practice of pharmacy, 22nd ed., L. A. Loyd, Ed. London, Philadelphia: Pharmaceutical Press, 2013, pp. 777-798.
K. P. Gupta, „Solutions and phase equilibrria," in Remington The science and practice of pharmacy, 22nd ed., L. A. Loyd, Ed. London, Philadelphia: Pharmaceutical Press, 2013, pp. 588-590.
J. Parasrampuria, "Liquid oral preparations," in Encyclope dia of pharmaceutical technology, vol. 9., J. Swarbrick and J. C. Boylan, Eds.: New York, Basel, Hong Kong: Marcel Dekker Inc., 1994, pp. 41-59.
M. Gibaldi, S. Feldman, Establishment of sink conditions in dissolution rate determinations, theoretical considerations and application to nondisintegrating dosage forms, J Pharm Sci,1967, 56, 1238-1242.
R. Agarwal, V. Gupta, Cyclodextrins – a review on pharma ceutical application for drug delivery, Inter J Pharm Frontier Res, 2012, 2, 96-113.
A. A. N. Lima, J. L. S. Sobrinho, R. A. C. Corrêa, P. J. Neto Rolim, Alternative technologies to improve solubility of poorly water soluble drugs, Lat Am J Pharm, 2008, 27, 789-797.
ICH topic Q3C (R4) impurities: guideline for residual sol vents, center for drug evaluation and research (CDER), step 5, 2009, pp.1-22.
Council of Europe, The European pharmacopoeia, 7th ed., vol. 2., European directorate for the quality of medicine (EDQM), Strasbourg, 2011, pp. 295-295.
V. Kumar and P. Hiremath, „Dissolution," in Remington The science and practice of pharmacy, 22nd ed., L. A. Loyd, Ed. London, Philadelphia: Pharmaceutical Press, 2013, pp. 435-436.
J. I. Wells and M. E. Aulton, "Preformulation," in Pharma ceutics The science of dosage form design, 2nd ed., E. M. Aulton, Ed., Edinburgh, etc.: Churchill Livingstone, 2001, pp. 224-252.
J. D. Higgins, W. L. Rocco, A stop along the drug development highway. Today`s chemist at work, 2003, 12, 22-26.
S. A. Howard, "Flow properties of solids," in Encyclopedia of pharmaceutical technology, 2th ed., vol. 2., J. Swarbrick and J. C. Boylan, Eds. New York, Basel: Marcel Dekker Inc., 2002, 1264-1271.
E. G. Granero, C. Ramachandran and G. L. Amido, "Gastrointenstinal dissolution and absorption of drug," in Drug bioavability: estimination of solubility, permeability, absorption and bioavailability, vol. 18. H. van de Waterbeemd Lennernäs and P. Arturrson, Eds. Weisenheim: Wiley-VCH, 2003, pp. 191-210.